Navigation Links
Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
Date:11/20/2013

DUBLIN, Nov. 20, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its participation at the 25th Annual Piper Jaffray Healthcare Conference in New York, NY.

Bruce C. Cozadd, chairman and chief executive officer, will provide a corporate overview on Tuesday, December 3, at 8:30 a.m. EST / 1:30 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
2. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
3. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
4. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
5. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
6. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
7. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
8. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
9. Biopharmaceuticals - A Global Market Overview
10. Star Scientific and Rock Creek Pharmaceuticals Announce the Publication of a Peer-Reviewed Article about the ASAP Clinical Trial Showing Immune System Support in Hashimotos Thyroiditis
11. Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):